Alain M Monnier

Summary

Country: France

Publications

  1. ncbi The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1-98
    A Monnier
    Centre Hospitalier Belfort Montbeliard, 1 Rue du docteur flamand, 25209 Montbeliard Cedex, France
    Breast 15:S21-9. 2006
  2. ncbi Adjuvant trials: Aromatase inhibitors in early breast cancer--are they alike?
    Alain Monnier
    Head of Medical Oncology, Centre Hospitalier Belfort Montbeliard, 1 Rue du docteur flamand, 25209 Montbeliard Cedex, France
    Cancer Treat Rev 32:532-40. 2006
  3. ncbi Refining the postmenopausal breast cancer treatment paradigm: the FACE trial
    Alain Monnier
    Centre Hospitalier Belfort Montbeliard, 25206 Montbeliard Cedex, France
    Expert Rev Anticancer Ther 6:1355-9. 2006
  4. ncbi Effects of adjuvant aromatase inhibitor therapy on lipid profiles
    Alain Monnier
    Centre Hospitalier A Boulloche, Oncology Medical Department, 1 Rue du docteur flamand, 25209 Montbeliard Cedex, France
    Expert Rev Anticancer Ther 6:1653-62. 2006
  5. ncbi The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer
    Alain M Monnier
    Department of Medical Oncology, Centre Hospitalier A Boulloche, Montbeliard Cedex, France
    Expert Rev Anticancer Ther 7:627-34. 2007
  6. ncbi Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer
    A Monnier
    Centre Hospitalier Belfort Montbeliard, Montbeliard, France
    Ann Oncol 18:viii36-44. 2007

Detail Information

Publications6

  1. ncbi The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1-98
    A Monnier
    Centre Hospitalier Belfort Montbeliard, 1 Rue du docteur flamand, 25209 Montbeliard Cedex, France
    Breast 15:S21-9. 2006
    ..81; P=0.003), especially reducing distant metastases (hazard ratio 0.73; P=0.0012). These results establish letrozole as part of standard adjuvant therapy for postmenopausal women with endocrine-responsive breast cancer...
  2. ncbi Adjuvant trials: Aromatase inhibitors in early breast cancer--are they alike?
    Alain Monnier
    Head of Medical Oncology, Centre Hospitalier Belfort Montbeliard, 1 Rue du docteur flamand, 25209 Montbeliard Cedex, France
    Cancer Treat Rev 32:532-40. 2006
    ..Results of trials currently under way should determine the optimal use of the aromatase inhibitors in breast cancer therapy...
  3. ncbi Refining the postmenopausal breast cancer treatment paradigm: the FACE trial
    Alain Monnier
    Centre Hospitalier Belfort Montbeliard, 25206 Montbeliard Cedex, France
    Expert Rev Anticancer Ther 6:1355-9. 2006
    ..The results are expected to further refine the treatment paradigm for breast cancer in postmenopausal patients with node-positive disease...
  4. ncbi Effects of adjuvant aromatase inhibitor therapy on lipid profiles
    Alain Monnier
    Centre Hospitalier A Boulloche, Oncology Medical Department, 1 Rue du docteur flamand, 25209 Montbeliard Cedex, France
    Expert Rev Anticancer Ther 6:1653-62. 2006
    ..This review discusses the current understanding of the influence of lipid levels on cardiovascular risk in women and presents key findings on the effects of adjuvant aromatase inhibitor therapy on lipid profiles...
  5. ncbi The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer
    Alain M Monnier
    Department of Medical Oncology, Centre Hospitalier A Boulloche, Montbeliard Cedex, France
    Expert Rev Anticancer Ther 7:627-34. 2007
    ..e., anastrozole or letrozole) and information as to the optimal treatment strategy (i.e., initial adjuvant aromatase inhibitor therapy or sequential adjuvant aromatase inhibitor therapy)...
  6. ncbi Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer
    A Monnier
    Centre Hospitalier Belfort Montbeliard, Montbeliard, France
    Ann Oncol 18:viii36-44. 2007
    ....